New funding for depression and Alzheimer’s research

Many congratulations to Jonathan Cavanagh and colleagues as the Wellcome Trust has approved funding for Phase 2 of their consortium on the neuroimmunology of mood and Alzheimer’s (NIMA). This funding, matched by industry collaborators,  will allow proof of concept first stage clinical trials of entirely new molecular targets for major depressive disorder and Alzheimer’s disease.

First published: 11 December 2017

<< News